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Abstract
Aims/hypothesis Diabetes mellitus type 2 is characterised
by hyperglucagonaemia, resulting in hepatic glucose pro-
duction and hyperglycaemia. Considering that insulin
inhibits glucagon secretion and gene transcription, hyper-
glucagonaemia in the face of hyperinsulinaemia in diabetes
mellitus type 2 suggests that there is insulin resistance also
at the glucagon-producing pancreatic islet alpha cells.
However, the molecular mechanism of alpha cell insulin
resistance is unknown. Therefore, the effect of molecules
implicated in conferring insulin resistance in some other
tissues was investigated on insulin-induced inhibition of
glucagon gene transcription in alpha cells.
Methods Reporter gene assays and biochemical techniques
were used in the glucagon-producing hamster pancreatic
islet alpha cell line InR1-G9.
Results From among 16 agents tested, chronic insulin
treatment was found to abolish insulin-induced inhibition
of glucagon gene transcription. Overproduction of consti-
tutively active protein kinase B (PKB) still inhibited
glucagon gene transcription after chronic insulin treatment;
together with a markedly reduced insulin-induced phos-
phorylation and, thus, activation of PKB, this indicates that
targets upstream of PKB within the insulin signalling
pathway are affected. Indeed, chronic insulin treatment
markedly reduced IRS-1 phosphorylation, insulin receptor
(IR) autophosphorylation and IR content. Cycloheximide
and in vivo labelling experiments attributed IR down-
regulation to enhanced degradation.
Conclusions/interpretation These results show that an
extended exposure of alpha cells to insulin induces IR
downregulation and loss of insulin-induced inhibition of
glucagon gene transcription. They suggest that hyper-
insulinaemia, through IR downregulation, may confer
insulin resistance to pancreatic islet alpha cells in diabetes
mellitus type 2.
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Introduction
Diabetes mellitus type 2 is associated with insulin resis-
tance of peripheral organs such as skeletal muscle, adipose
tissue and the liver [1]. Although the genetic bases and the
cellular events that underlie insulin resistance are poorly
understood, a great variety of factors have been shown to
be involved in the development of this condition in these
tissues. Among those factors are pro-inflammatory cyto-
kines, NEFA, hyperinsulinaemia, reactive oxygen species
and the mammalian homologue of Drosophila tribbles 3
(TRB3), as well as drugs such as glucocorticoids and the
immunosuppressants ciclosporin A and tacrolimus [1–3].
These factors can promote insulin resistance through
several mechanisms. Pro-inflammatory cytokines such as
tumour necrosis factor-α (TNF-α) and IL-6, for example,
act through classic receptor-mediated processes to stimulate
c-Jun N-terminal kinase 1-mediated serine phosphorylation
of IRS-1, IκB kinase-mediated nuclear factor-κB activation,
and induction of suppressor of cytokine signalling 3 [1].
Furthermore, diabetes mellitus type 2 is associated with
hyperglucagonaemia [4–11]. The peptide hormone gluca-
gon is synthesised in the islets of Langerhans within the
pancreas. Islets synthesise different hormones in distinct
cell types. Pancreatic islet alpha cells synthesise and secrete
glucagon, which in combination with insulin, synthesised
by pancreatic beta cells, regulates blood glucose concen-
trations. Insulin increases peripheral glucose uptake and
opposes hepatic glucose production, while glucagon balan-
ces the effect of insulin by increasing hepatic glucose
production and opposing hepatic glucose storage [9–11].
Glucagon-producing alpha cells are mainly located in the
peripheral regions of the islets of Langerhans surrounding
the insulin-producing beta cells. Therefore, they are
exposed to high concentrations of insulin [9–11]. Acting
directly on alpha cells, insulin inhibits glucagon secretion
and gene transcription [12, 13]. Previous studies have
shown that insulin inhibits glucagon gene transcription
through the activation of phosphatidylinositol 3-kinase
(PI3K) and protein kinase B (PKB), leading to inhibition
of the activity of the transcription factor Pax6, which is
essential for the alpha cell-specific activation of the
glucagon gene [12, 13]. The paracrine inhibition of
glucagon gene transcription by insulin is an important
mechanism in blood glucose control. Consequently, in
diabetic patients the relative hyperglucagonaemia contrib-
utes to hyperglycaemia in these patients [4–11].
The elevated glucagon levels in the face of hyper-
insulinaemia in diabetes mellitus type 2 suggest that there is
insulin resistance also of pancreatic islet alpha cells [4–11].
However, what confers insulin resistance to pancreatic islet
alpha cells is unknown. Therefore, in the present study, the
effect of messenger molecules that have been implicated in
conferring insulin resistance to some other tissues on the
inhibition by insulin of glucagon gene transcription in
pancreatic islet alpha cells was investigated.
Methods
Materials RPMI 1640 cell culture medium, fetal bovine
serum, penicillin/streptomycin solution and trypsin/EDTA
were from GIBCO BRL (Karlsruhe, Germany). Bromophe-
nol blue, CellLytic M cell lysis reagent, cycloheximide,
chloroquine, lactacystin, sodium deoxycholate, sodium
fluoride, sodium orthovanadate, okadaic acid, porcine
insulin, Protein G agarose beads and Triton X-100 were
from Sigma-Aldrich (Steinheim, Germany). BSA, glycerol,
leupeptin, pepstatin, phenylmethylsulfonylfluoride (PMSF),
SDS and TRIS were from Applichem (Darmstadt, Ger-
many). The antibodies for PKB, phospho-Ser473-PKB,
insulin receptor (IR)-β, phospho-Tyr1150/1151-IR and
IRS-1 were from Cell Signaling (Danvers, MA, USA).
The IR antibody (Ab-3/29B4) for labelling experiments
was from Calbiochem (Darmstadt, Germany). The antibody
for phospho-Tyr612-IRS-1 was from Biosource (Camarillo,
CA, USA). The glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) antibody was from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). The β-catenin antibody was
from BD Biosciences (Erembodegem, Belgium). The mono-
clonal antibody against β-arrestin 1 and 2 was from
Bünemann et al. [14]. [35S]Methionine (37 TBq/mmol)
was from Amersham (Munich, Germany).
Plasmid constructs The plasmid −350GluLuc [12] has been
previously described. The plasmid pGFPtpz-cmv[R] (GFP,
green fluorescent protein) was from Canberra-Packard
(Dreieich, Germany). The expression vectors encoding
myr-PKB (pCMV4-PKBmyr) and myr-PKB-K179M
(pCMV4-PKBmyr-K179M) have been previously described
[13]. The expression vector encoding TRB3 (pDNA3-FT-
TRB-3) was generously provided by S. Herzig, Heidelberg,
Germany.
Cell culture and transfection of DNA The glucagon-
producing hamster pancreatic islet cell line InR1-G9 [12,
15] was grown in RPMI 1640 medium supplemented with
10% (vol./vol.) fetal bovine serum, 100 U/ml penicillin and
100 μg/ml streptomycin. Cells were trypsinised and trans-
fected in suspension by the diethylaminoethyl-dextran
method [16] with 2 μg of reporter plasmid and the indicated
expression vector per 6 cm dish. In all experiments, 0.5 μg
of cytomegalovirus-GFP plasmid (pGFPtpz-cmv[R]) per
6 cm dish was cotransfected to check for transfection
efficiency. Twenty-four hours after transfection, the cells
were washed once with PBS and the medium was replaced
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by a serum-free medium containing 0.5% (wt/vol.) BSA
supplemented with antibiotics. When indicated, cells were
treated with increasing insulin concentrations 23 h before
harvest. Cells extracts were prepared 48 h after transfection
[16]. Luciferase activity was measured as described
previously [16], and GFP was measured in cell extracts
using the FluoroCount microplate fluorometer (Packard).
Immunoblots For PKB analysis, cells were lysed in pre-
heated 1× Laemmli buffer (0.25 mg/ml bromophenol blue,
10% (vol./vol.) glycerol, 2% (wt/vol.) SDS, 62.5 mmol/
l TRIS pH 6.8 and 2.5% (vol./vol.) β-mercaptoethanol),
homogenised five times with a syringe (27 G 3/4 inch
needle), and boiled for 5 min before 10% (wt/vol.) SDS-
PAGE was performed. Cell lysates for IR and IRS-1
analysis were prepared in ice-cold CellLytic M Cell Lysis
Reagent (Sigma-Aldrich) supplemented with the following
inhibitors: 1 μg/ml leupeptin, 50 mmol/l sodium fluoride,
2 mmol/l sodium orthovanadate, 1 μg/ml pepstatin,
1 mmol/l PMSF and 400 nmol/l okadaic acid. Cells were
kept on ice for 5 min, followed by mechanical detachment
by means of a scraper. Cells were centrifuged for 15 min at
12,000×g. Aliquots of the cell lysates were boiled for 5 min
after addition of 4× Laemmli buffer. SDS-PAGE analysis of
IR and IRS-1 was performed by using 7.5 and 6% (wt/vol.)
polyacrylamide gels, respectively. Detection of PKB,
phospho-Ser473-PKB, IR, phospho-Tyr1150/1151-IR and
IRS-1 was performed with specific antibodies (Cell
Signaling). Detection of phospho-Tyr612-IRS-1 was
performed with an antibody from Biosource. Detection
of β-arrestin 1 and 2 was performed using a monoclonal
antibody prepared by Bünemman et al. [14]. All trans-
ference procedures were performed by semi-wet transfer
with a three-buffer system (buffer 1: 20% [vol./vol.]
methanol, 300 mmol/l TRIS, pH 11.3; buffer 2: 20%
[vol./vol.] methanol, 25 mmol/l TRIS, pH 10.5; buffer 3:
20% [vol./vol.] methanol, 25 mmol/l TRIS, pH 9.0),
except for the IRS-1 transference, which required wet
transfer with only one buffer (20% [vol./vol.] methanol,
10% [vol./vol.] 10× TRIS–glycine buffer [1.9 mol/l gly-
cine, 250 mmol/l TRIS]). For IR experiments, equal
loading was monitored by GAPDH immunoblotting. After
incubation with the appropriate primary antibody and
horseradish peroxidase-coupled secondary antibody
(Amersham Biosciences, Freiburg, Germany), the signal
was visualised by enhanced chemiluminescence (Amer-
sham Biosciences). Cytosolic and membrane fractions
from InR1-G9 cells for β-arrestin immunoblotting were
prepared as described [17].
Biosynthetic labelling with [35S]methionine Labelling of the
IR of InR1-G9 cells with [35S]methionine was performed as
previously described [18]. InR1-G9 cells were grown in
RPMI 1640 medium containing 10% (vol./vol.) fetal bovine
serum, 100 units/ml penicillin and 100 μg/ml streptomycin
[16]. Cells were treated with insulin (100 nmol/l) 2 h after
plating. Twenty-two hours later, cells were washed twice
with PBS and were starved for 1 h in methionine-free
medium supplemented with 5% (vol./vol.) fetal bovine
serum and insulin (100 nmol/l), followed by incubation with
[35S]methionine (1.85 MBq/ml) at 37°C for 2 h. Cells were
washed twice with cold PBS and 200 μl of lysis buffer
(50 mmol/l HEPES pH 7.5 containing 150 mmol/l NaCl, 1%
[vol./vol.] Triton X-100, 5 mmol/l EDTA, 5 mmol/l EGTA,
20 mmol/l sodium pyrophosphate, 1 mmol/l sodium ortho-
vanadate, 20 mmol/l sodium fluoride and 1 mmol/l PMSF)
was added to the cells. After 5 min, cells were scraped and
were homogenised five times with a syringe (27 G 3/4 inch
needle). Cell lysates were centrifuged for 15 min at 18,000 g
(4°C), and the supernatant fraction was transferred to a new
2 ml tube. Immunoprecipitation was performed by mixing
200 μl of cell lysate with 1 μg of IR-β antibody (Ab3/29B4;
Calbiochem). This cell lysate–antibody mix was incubated
with gentle rocking overnight at 4°C. Protein G agarose
beads (25 μl of a 50% [vol./vol.] bead slurry) were added to
the lysate–antibody mix and were incubated with gentle
rocking for 2 h at 4°C. The complex was centrifuged for
15 min at 210 g (4°C) and the supernatant fraction was
discarded. The beads were washed five times with cell lysis
buffer and the pellet was resuspended with 20 μl of 4×
Laemmli buffer, vortexed and centrifuged for 1 min. The
samples were boiled for 5 min before loading on to a 7.5%
(wt/vol.) SDS gel. Immunoprecipitation results were ana-
lysed using a Fuji phosphorimaging device (Raytest-Fuji,
Straubenhardt, Germany).
Isolation of islets, RNA isolation, RT-PCR and mRNA
quantification Mouse islets (strain NMRI from the Centre of
animal experimental facility at the University Göttingen,
Germany) were isolated. All animal studies were conducted
according to the National Institutes of Health’s guidelines for
care and use of experimental animals and were approved by
the Committee on Animal Care and Use of the local
institution and state. Isolation of islets and their culture was
performed as described previously [3]. Islets were cultured in
RPMI 1640 supplemented with 10% (vol./vol.) fetal bovine
serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and
5 mmol/l glucose. After 1 and 23 h, respectively, preincu-
bation islets were treated with 100 nmol/l insulin for 23 or
46 h or left untreated. RNA isolation, RT-PCR and mRNA
quantification were performed as described previously [19]
using the same primers.
Statistical analysis All results are expressed as means±
SEM. Statistical significance was calculated with ANOVA
followed by the indicated tests using the software Statistica
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(StatSoft, Hamburg, Germany). A value of p<0.05 was
considered significant.
Results
Effect of factors that have been shown to confer insulin
resistance to some other tissues, on insulin-induced
inhibition of glucagon gene transcription in InR1-G9
cells A reporter gene containing 350 bp of the 5′-flanking
region of the rat glucagon gene (construct −350GluLuc
[12]) was transiently transfected into glucagon-producing
InR1-G9 cells. Treatment of InR1-G9 cells with insulin
inhibited glucagon gene transcription in a dose-dependent
fashion (Fig. 1a), as previously shown [12, 13]. The
maximal inhibition by insulin was by about 60% with an
IC50 value of 0.37 nmol/l (Fig. 1a). A great variety of factors
have been shown before to be involved in the development
of insulin resistance in skeletal muscle, adipose tissue or the
liver, including pro-inflammatory cytokines, NEFA, hyper-
insulinaemia, reactive oxygen species and the mammalian
homologue of TRB3, as well as drugs such as glucocorti-
coids and the immunosuppressants ciclosporin A and
tacrolimus [1–3, and references therein]. The effect of these
factors on the insulin-induced inhibition of glucagon gene
transcription was investigated in the InR1-G9 pancreatic islet
alpha cell line (Tables 1 and 2).
From the 16 treatments tested, 14 did not interfere with
the insulin-induced inhibition of glucagon gene transcription
(Table 2). Some of these, however, changed basal glucagon
gene transcription (Table 1). As has been shown before,
8-Br-cAMP stimulated [20] and the immunosuppressants
slightly inhibited glucagon gene transcription by them-
selves [3, 16] (Table 1). TNF-α, NEFA and hydrogen
peroxide inhibited, while TRB3 stimulated basal glucagon
gene transcription (Table 1), which has not been reported
before.
Two treatments (IL-1β and chronic insulin) were found to
interfere with the insulin-induced inhibition of glucagon gene
transcription (Table 2). IL-1β reduced the inhibition by
insulin by about 70% (Table 2). However, it also inhibited
basal glucagon gene transcription by about 75% (Table 1).
When the treatment of InR1-G9 cells with insulin was
extended from 23 to 46 h, the inhibition by insulin of
glucagon gene transcription was no longer observed (Fig. 1b,
Table 2). Treatment with insulin for 23 h reduced glucagon
mRNA to 58% in InR1-G9 cells and to 69% in primary
murine islets, consistent with the previous findings [21].
Glucagon mRNA levels were restored in InR1-G9 cells as
well as in islets after a 46 h treatment with insulin (Fig. 1c,d).
This indicates that alpha cells lose their insulin responsive-
ness upon extended exposure to insulin (insulin-induced
insulin resistance of alpha cells).
Insulin-induced alpha cell insulin resistance: PKB action
and phosphorylation Insulin has been shown before to
inhibit glucagon gene transcription through the PI3K–PKB
signalling pathway [13]. As has been reported previously
[13], insulin induced the phosphorylation of PKB on
Ser473 in InR1-G9 cells within 10 min (Fig. 2a, left). This
phosphorylation is required for the activation of PKB [22].
However, after extended pretreatment of InR1-G9 cells
with insulin for 23 h, the insulin-induced phosphorylation
of PKB was markedly reduced (Fig. 2a, left) without a
change in the expression level of PKB (Fig. 2a, right).
In the absence of insulin, the expression of a constitu-
tively active form of PKB, myr-PKB, inhibited glucagon
gene transcription (Fig. 2b), whereas the kinase-dead
mutant myr-PKB-K179M had no effect (Fig. 2b), as has
been shown previously [13]. Insulin (23 h) inhibited
glucagon gene transcription (Fig. 2b) and myrPKB could
not further enhance this inhibition (Fig. 2b). Insulin
Fig. 1 Loss of insulin-induced inhibition of glucagon gene transcrip-
tion in a pancreatic islet alpha cell line upon extended exposure of the
cells to insulin. InR1-G9 cells were transfected with the plasmid
−350GluLuc. a Concentration–response curve for the inhibition by
insulin of glucagon gene transcription. Increasing concentrations of
insulin were added 23 h before harvest. b Loss of insulin-induced
inhibition of glucagon gene transcription upon prolonged treatment of
the cells with insulin. Insulin (100 nmol/l) was added 23 or 46 h
before harvest. The luciferase activities are expressed as percentage of
the mean value of the activity measured in the untreated controls.
Values are means±SEM of three independent experiments, each done
in duplicate (a), or four independent experiments, each done in
triplicate (b). †p<0.00005 (one-way ANOVA followed by Scheffé
test). c InR1-G9 cells were treated for 23 and 46 h with insulin
(100 nmol/l) before harvest or were left untreated. d Murine primary
islets were isolated and incubated in 5 mmol/l glucose. Islets were
treated with insulin (100 nmol/l) 23 and 46 h before harvest or were
left untreated. RNA was extracted, cDNA was transcribed and the
glucagon mRNA levels were quantified. Values are means ± SEM of
four different experiments. *p<0.05 (Student’s t test)
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treatment for 46 h no longer inhibited glucagon gene
transcription. Under this chronic insulin treatment, myrPKB
was still able to inhibit glucagon gene transcription, while
myr-PKB-K179M did not cause any inhibition (Fig. 2b).
Effect of insulin desensitisation by chronic insulin treatment
on IRS-1 phosphorylation, IR autophosphorylation and IR
content in alpha cells As demonstrated by a phosphotyr-
osine-specific immunoblot (antiphospho-Tyr612-IRS-1), in-
sulin stimulated IRS-1 phosphorylation within 10 min
(Fig. 3). However, after extended pretreatment of InR1-G9
cells with insulin for 23 h, the insulin-induced phosphory-
lation of IRS-1 was reduced by 86% (Fig. 3). The extended
treatment with insulin (23 h 10 min) did not change the level
of IRS-1 (not shown).
Phosphotyrosine-specific immunoblotting (antiphospho-
Tyr1150/1151-IR) revealed that the insulin-induced autophos-
phorylation of the IR was virtually abolished after extended
pretreatment of InR1-G9 cells with insulin for 23 h (Fig. 4,
left). At the same time, insulin pretreatment for 23 h reduced
the content of the IR by about 90% (Fig. 4, right). Similarly
to the effect of 100 nmol/l insulin (Fig. 4), the treatment of
InR1-G9 cells for 23 h 10 min with 1 nmol/l insulin
decreased the content of the IR by about 80% (not shown).
The time-course of these effects is shown in Fig. 5a.
Insulin treatment of InR1-G9 cells decreased IR autophos-
phorylation and IR content by about 50% within 4 h and by
more than 90% within 8 h (Fig. 5a). The insulin-induced IR
downregulation was completely reversible (Fig. 5b). When
insulin was withdrawn after 24 h of treatment, IR content
Table 1 Effect of different treatments on basal glucagon gene







None – 10 100±5
10 nmol/l insulin 23 10 52±9***
10 ng/ml TNF-α 24 8 93±7
10 ng/ml TNF-α 46 6 94±6
100 ng/ml TNF-α 24 4 77±4***
20 ng/ml IL-6 24 6 121±8
20 ng/ml IL-6 46 6 105±4
10 ng/ml IL-1β 24 6 25±1***
1 mmol/l 8-Br-cAMP 24 8 190±26**
1 mmol/l 8-Br-cAMP 46 6 261±40**
1 μmol/l dexamethasone 24 6 78±8*
1 μmol/l dexamethasone 46 8 114±12
300 nmol/l ciclosporin A 24 6 80±5**
300 nmol/l ciclosporin A 46 4 96±5
10 nmol/l tacrolimus 24 4 85±5
10 nmol/l tacrolimus 46 6 82±4**
0.2 mmol/l palmitic acid 24 12 104±6
0.2 mmol/l stearic acid 24 14 132±8**
0.4 mmol/l oleic acid 24 12 82±5***
0.2 mmol/l oleic acid+0.2 mmol/l
palmitic acid
24 12 114±24
0.4 mmol/l linoleic acid 24 10 65±7***
0.4 mmol/l linolenic acid 24 10 46±4***
10 μmol/l H2O2 24 15 83±2***
30 μmol/l H2O2 24 15 71±2***
TRB3 - 12 277±17***
Values are means±SEM of the number of experiments indicated (n)
InR1-G9 cells were transfected with −350GluLuc. Treatments started
at the time indicated before harvest. TRB3, an expression vector
encoding TRB3 was cotransfected (2 μg/dish). The luciferase
activities are expressed as percentage of the mean value in each
experiment of the activity measured in the untreated controls
*p<0.05, **p<0.01, ***p<0.001 (Student’s t test)
Table 2 Effect of different treatments on the insulin-induced







None 23 10 100
10 ng/ml TNF-α 24 8 113
10 ng/ml TNF-α 46 6 107
100 ng/ml TNF-α 24 4 117
20 ng/ml IL-6 24 6 103
20 ng/ml IL-6 46 6 101
10 ng/ml IL-1β 24 6 27a
1 mmol/l 8-Br-cAMP 24 8 68
1 mmol/l 8-Br-cAMP 44 6 82
1 μmol/l dexamethasone 24 6 95
1 μmol/l dexamethasone 46 8 112
300 nmol/l ciclosporin A 24 6 76
300 nmol/l ciclosporin A 46 4 124
10 nmol/l tacrolimus 24 4 87
10 nmol/l tacrolimus 46 6 97
0.2 mmol/l palmitic acid 24 6 105
0.2 mmol/l stearic acid 24 6 104
0.4 mmol/l oleic acid 24 8 113
0.2 mmol/l oleic acid+0.2 mmol/l
palmitic acid
24 6 143
0.4 mmol/l linoleic acid 24 4 76
0.4 mmol/l linolenic acid 24 4 115
10 μmol/l H2O2 24 15 100
3 μmol/l H2O2 24 15 102
TRB3 – 12 111
100 nmol/l insulin (chronic insulin) 46 8 0a
Values are shown as the mean of the number of experiments indicated (n)
InR1-G9 cells were transfected with −350GluLuc, and insulin was
added in increasing concentrations 23 h before harvest. The treatments
started to the time indicated before harvest. TRB3, an expression
vector encoding TRB3 was cotransfected (2 µg per dish). The insulin
concentration–response curve under treatment was compared with an
insulin concentration–response curve without treatment run in parallel
in each experiment. An example of a concentration–response curve is
shown in Fig. 1a. The maximal inhibition by insulin under treatment
(Insulin Emax) is expressed as percentage of the maximal inhibition by
insulin without treatment
a Indicates the two treatments that virtually abolished the insulin-
induced inhibition of glucagon gene transcription. No changes in the
IC50 value of insulin were observed for any treatment (not shown)
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recovered to about 50% of controls within 9 and 5 h in the
presence or absence of serum, respectively (Fig. 5b).
Effect of insulin desensitisation by chronic insulin treatment
on IR synthesis and degradation The labelling of the IR
with [35S]methionine was not changed by the treatment of
InR1-G9 cells with insulin for 24 h (data not shown),
suggesting that chronic (24 h) insulin treatment does not
inhibit IR synthesis.
In the presence of the protein synthesis inhibitor
cycloheximide, insulin enhanced the decrease in IR levels
(Fig. 6), suggesting that insulin stimulates the degradation
of the IR.
Further experiments were performed to characterise the
degradation pathways involved. The inhibitor of proteaso-
mal degradation, lactacystin [23], did not prevent the
insulin-induced downregulation of the IR (Fig. 7a). How-
ever, lactacystin effectively prevented the degradation of β-
catenin, induced by the thiazolidindione rosiglitazone
bound to the peroxisome-proliferator activated receptor γ
(Electronic supplementary material [ESM] Fig. 1) [24]. β-
Arrestins were found to be heavily produced in InR1-G9
cells (Fig. 7b) and have been suggested to interact with the
IR [25]. However, insulin did not induce a cytosol-to-
membrane translocation of β-arrestins in InR1-G9 cells
Fig. 2 Effect of chronic insulin treatment on the insulin-induced PKB
phosphorylation and PKB-induced inhibition of glucagon gene
transcription in pancreatic islet alpha cells. a, b PKB phosphorylation
and level. InR1-G9 cells were treated with insulin (100 nmol/l) for
10 min or 23 h 10 min or left untreated. Cell lysates were subjected to
immunoblotting with antiphospho-Ser473-PKB (Anti-P-Ser473-PKB;
a) or anti-PKB antibodies (b). Representative immunoblots are shown
in the upper panels. Lower panels, densitometry; values are
normalised to the 10 min insulin group (a) or untreated group (b).
Values are means±SEM of four independent experiments. P-PKB,
phospho-Ser473-PKB. *p<0.05 (Student’s t test). c PKB-induced
inhibition of glucagon gene transcription. InR1-G9 cells were trans-
fected with −350GluLuc (black bars) together with plasmids encoding
myr-PKB (hatched bars) or myr-PKB-K179M (white bars), as
indicated. Insulin (100 nmol/l) was added 23 or 46 h before harvest.
The luciferase activities are expressed as percentage of the mean value
of the activity measured in the controls (no insulin, no myr-PKB, no
myr-PKB-K179M). Values are means±SEM of three independent
experiments, each performed in triplicate. *p<0.05, †p<0.00005 (one-
way ANOVA followed by Scheffé test)
Fig. 3 Effect of chronic insulin treatment on the insulin-induced IRS-
1 phosphorylation in pancreatic islet alpha cells. InR1-G9 cells were
treated with insulin (100 nmol/l) for 10 min or 23 h 10 min or left
untreated. Cell lysates were subjected to immunoblotting with
antiphospho-Tyr612-IRS-1 (P-IRS-1 Tyr612) antibodies. A represen-
tative immunoblot is shown in the upper panel. Lower panel,
densitometry; values are normalised to the 10 min insulin group.
Values are means±SEM of three independent experiments. †p<
0.00001 (Student’s t test). P-IRS, phosphorylated IRS
Fig. 4 Effect of chronic insulin treatment on insulin-induced IR
autophosphorylation and IR levels in pancreatic islet alpha cells.
InR1-G9 cells were treated with insulin (100 nmol/l) for 10 min or
23 h 10 min or left untreated. Cell lysates were subjected to
immunoblotting with antiphospho-Tyr1150/Tyr1151-IR (Anti-P-
Tyr1150/1151-IR; a) or anti-IR-β (Anti-IR; b) antibodies. Represen-
tative immunoblots are shown in the upper panels. Lower panels,
densitometry; values are normalised to the 10 min insulin group (left)
or untreated group (right). Values are means ± SEM of three
independent experiments. *p<0.05, †p<0.00001 (Student’s t test). P-
IR, phosphorylated IR
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(Fig. 7b), although, serving as positive control, chemokine
(C–C motif) ligand 5 (CCL5) stimulated membrane
translocation of β-arrestins in rat basophilic leukaemia
cells stably expressing the human chemokine receptor 5, as
has been shown before [17]. The lack of insulin-induced
membrane translocation provides no evidence for an
interaction between the liganded IR and β-arrestins in
glucagon-producing alpha cells. The lysosomotropic agent
chloroquine [26–28] reduced insulin-induced IR down-
regulation, as in the presence of chloroquine the treatment
of InR1-G9 cells with insulin for 8 h did not produce a
significant decrease of IR levels (Fig. 7c). Longer treatment
periods could not be studied because 25 h chloroquine
treatment exerted detrimental effects on the viability of
InR1-G9 cells (Fig. 7c and data not shown).
Discussion
The IR is a transmembrane receptor that belongs to the
tyrosine kinase family of receptors. Insulin binding induces
receptor autophosphorylation followed by IRS recruitment
and phosphorylation at multiple tyrosine residues, which then
serve as starting points for diverse signalling pathways,
including the PI3K–PKB signalling pathway to the glucagon
gene in pancreatic islet alpha cells [12, 13]. The responsive-
ness of a target organ to insulin is subject to regulation. This
phenomenon is best demonstrated by the well-known
presence of insulin resistance of skeletal muscle, adipose
tissue and the liver in diabetes mellitus type 2 [1]. In this
disease, insulin resistance is evidently present also at the
pancreatic islet alpha cells, as is indicated by hyperglucago-
naemia in the face of hyperinsulinaemia [4–11]. Diabetes
mellitus type 2 is thus indeed a bihormonal disease with
relative insulin deficiency and glucagon excess, as already
stated by R. H. Unger and L. Orci more than 30 years ago
[8]. However, to date there is no information about the agents
that induce insulin resistance at the level of the pancreatic
islet alpha cells. The results of the present study now suggest
that hyperinsulinaemia with subsequent IR downregulation
Fig. 5 Time-course of the effect of chronic insulin treatment on
insulin-induced IR autophosphorylation and IR levels and its
reversibility in pancreatic islet alpha cells. a, b Time-course. InR1-
G9 cells were treated with insulin (100 nmol/l) for the time indicated
or left untreated. Cell lysates were subjected to immunoblotting with
antiphospho-Tyr1150/Tyr1151-IR (Anti-P-Tyr1150/1151-IR; a) or
anti-IR-β (Anti-IR, b) antibodies. Representative immunoblots are
shown in the upper panels. Lower panels, densitometry, values are
normalised to the 5 min insulin group (a) or untreated group (b).
Values are means±SEM of four independent experiments. *p<0.05,
†p<0.005 (paired Student’s t test). c Reversibility. InR1-G9 cells were
treated with insulin (100 nmol/l) for 24 h or left untreated (Ctrl).
Insulin was then withdrawn and the cells were incubated without
adding insulin for the time indicated (Recovery) in the presence
(Serum) or absence of serum (BSA, which replaced serum proteins).
Cell lysates were subjected to immunoblotting with anti-IR-β (Anti-
IR) antibodies. Upper panel, immunoblot. Lower panel, densitometry.
A representative experiment of three independent experiments is
shown
Fig. 6 Effect of insulin on IR levels in the presence of the protein
synthesis inhibitor cycloheximide in pancreatic islet alpha cells.
Cycloheximide alone (50 μg/ml) (black circles) or cycloheximide
(50 μg/ml) plus insulin (100 nmol/l) (white circles) was added to
InR1-G9 cells, and the cells were then incubated for the time
indicated. Cell lysates were subjected to immunoblotting with anti-
IR-β antibody. Upper panel, immunoblot. Lower panel, densitometry,
normalised to the untreated group
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may be one of the mechanisms that confer insulin resistance
to glucagon-producing pancreatic islet alpha cells.
From among the 16 agents that are considered to be
involved in the development of insulin resistance in some
other tissues [1], and which were tested in the present study,
14 did not relieve alpha cells of the insulin-induced
inhibition of glucagon gene transcription under the experi-
mental conditions used. Nevertheless, TNF-α, non-saturated
fatty acids and hydrogen peroxide inhibited glucagon gene
transcription by themselves, which has not been reported
before. The mechanisms and significance of these effects
remain to be studied. The inhibition by TNF-α, for example,
could play a role in sepsis-induced hypoglycaemia [29].
The mammalian homologue TRB3 has been reported to
block PKB activation by insulin in the liver [2]. It
stimulated glucagon gene transcription, which is consistent
with PKB inhibition, if basal glucagon gene transcription is
restricted by PKB. If so, TRB3 appears not to reach critical
cellular compartments, since it did not prevent the insulin-
induced inhibition of glucagon gene transcription, although
this effect is mediated by PKB activation [13].
One of the two messenger molecules that were tested in the
present study, and which abolished the insulin-induced
inhibition of glucagon gene transcription, was IL-1β. This
effect of IL-1β is, however, difficult to interpret, since IL-1β
markedly decreased basal glucagon gene transcription by
itself. This decrease also questions a role for IL-1β in the
development of alpha cell insulin resistance, because it
contrasts with elevated glucagon levels in diabetes mellitus
type 2.
The other agent that was found in the present study to
abolish the insulin-induced inhibition of glucagon gene
transcription was insulin itself: a prolonged action of
insulin on alpha cells led to a loss of the insulin response.
Factors such as secinH3, TNF-α and fatty acids have been
shown to interfere with insulin signalling at a level down-
stream of the IR when conferring insulin resistance to some
other tissues [1, 30]. In the insulin-desensitised alpha cell
line, the overproduction of PKB still inhibited glucagon
gene transcription and the insulin-induced phosphorylation,
and thus activation of PKB was markedly reduced, all
indicating that the insulin-induced defect in insulin signal-
ling is upstream of PKB. The location of the alteration
responsible for the insulin-resistant state of alpha cells may
reside in the IR, since chronic insulin markedly reduced
IRS-1 phosphorylation, IR autophosphorylation and IR
levels. IR downregulation was a time-dependent and
reversible process. The insulin-induced decrease in IR
autophosphorylation was synchronous with and appears thus
to be secondary to the decrease in IR levels. The IR levels
were decreased by insulin to about 50% within 4 h and by
more than 90% within 8 h. This time-course suggests that the
concentration–response curve shown in Fig. 1 may underes-
timate the inhibition by insulin of glucagon gene transcrip-
tion, because of rapid desensitisation. Chronic insulin
treatment did not change the labelling of the IR with [35S]
methionine but did enhance its elimination in the presence of
the protein synthesis inhibitor cycloheximide, indicating that
IR downregulation was due to enhanced degradation of the
IR. β-Arrestins are best known for complex formation with
Fig. 7 Examination of potential IR degradation pathways in pancre-
atic islet alpha cells. a Effect of the proteasome inhibitor lactacystin on
insulin-induced IR downregulation. InR1-G9 cells were incubated
with insulin (100 nmol/l; for 10 min or 24 h) in the presence or
absence of lactacystin (5 μmol/l; added 24 h 30 min before harvest).
Cell lysates were subjected to immunoblotting with anti-IR-β
antibody. Upper panel, immunoblot. Lower panel, densitometry,
normalised to the untreated group. b Effect of insulin on β-arrestin
levels in cytosolic and membrane fractions of InR1-G9 cells. InR1-G9
cells were treated with insulin (100 nmol/l) for the time indicated.
Cytosolic and membrane fractions were subjected to immunoblotting
with anti-β-arrestin antibodies. The CCL5-induced membrane trans-
location of β-arrestins in rat basophilic leukaemia cells (RBL) served
as positive control [16]. c Effect of the lysosomal degradation inhibitor
chloroquine on insulin-induced IR downregulation. InR1-G9 cells
were treated with insulin (100 nmol/l, for 8 or 24 h as indicated) in the
presence or absence of chloroquine (200 μmol/l, added at 9 or 25 h,
respectively, before harvest). Cell lysates were subjected to immuno-
blotting with anti-IR-β antibody. Upper panel, representative immu-
noblot. Lower panel, densitometry; values are normalised to the
untreated group (Ctrl). Black bars, 8 h insulin; grey bars, 24 h insulin.
Values are means±SEM of three independent experiments. *p<0.05;
n.s., not significant (Student’s t test)
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seven-transmembrane receptors following agonist binding
and receptor phosphorylation by G-protein-coupled receptor
kinases [14]. Binding of β-arrestin to the cytoplasmic
domain of seven-transmembrane receptors interrupts hetero-
trimeric G-protein interaction with the receptor [17]. Recent-
ly, β-arrestins have been implicated also in the ubiquitination
and downregulation of the insulin-like growth factor-1
receptor [31]. They are also able to associate with the
liganded IR [23] and may interfere with insulin signalling
[32]. However, insulin did not induce a cytosol-to-membrane
translocation of β-arrestins in alpha cells, providing no
evidence for an interaction of the IR with β-arrestins.
Furthermore, the inhibitor of proteasomal degradation,
lactacystin [23], did not prevent IR downregulation, whereas
the lysosomotropic agent chloroquine [26–28] reduced it to
some degree. When taken together, these results demonstrate
that a prolonged treatment of alpha cells with insulin
abolishes insulin-induced inhibition of glucagon gene tran-
scription; this desensitisation of alpha cells is associated with
and may be secondary to IR downregulation, which follows
from enhanced IR degradation that may involve lysosomal
pathways.
The novel finding of the present study is that insulin is
able to induce insulin resistance in pancreatic islet alpha
cells, as it does in skeletal muscle, fat and liver cells [1, 32–
37]. This finding may be of particular importance for the
understanding of diabetes mellitus type 2. Hyperinsulinae-
mia is a hallmark of diabetes mellitus type 2 and an early
event in the development of the disease. At early stages,
insulin resistance is overcome by an increase in insulin
secretion; this secondary hyperinsulinaemia together with
other metabolic derangements might contribute in a feed-
forward manner to progressive insulin resistance [1]. On the
other hand, hyperinsulinaemia can be the primary event.
Transgenic mice overproducing a dominant negative mu-
tant of carcinoembryonic antigen-related cell adhesion
molecule 1 (CEACAM1), which, as wild-type, promotes
insulin degradation in the liver, developed hyperinsulinae-
mia resulting from impaired insulin clearance; the hyper-
insulinaemia caused secondary insulin resistance [38].
Noteworthy, this insulin resistance was associated with a
decrease by 50% of the IR number in hepatocytes [38],
which is reminiscent of IR downregulation associated with
insulin resistance in pancreatic islet alpha cells, as observed
in the present study. Insulin-induced desensitisation may be
particularly relevant for alpha cells, which are located next
to insulin-producing beta cells within the pancreatic islets
[39] and are thus exposed to high insulin levels. Loss of the
pulsatile pattern of insulin secretion, as has been suggested
to occur in diabetes mellitus type 2 [40–42], leads to a
steady exposure of alpha cells to insulin, further promoting
insulin desensitisation. By providing direct evidence for
self-modulation by insulin of the insulin sensitivity in a
pancreatic islet alpha cell line, the present study suggests
that insulin-induced insulin resistance of pancreatic islet
alpha cells underlies the relative glucagon excess in diabe-
tes mellitus type 2.
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